Zhaolin Xu, MD, FRCPC, FCAP
Professor, Dept. of Pathology, Dalhousie University
Pulmonary Pathologist and Cytopathologist, QE II Health Sciences Centre
Senior Scientist, Beatrice Hunter Cancer Research Institute
5788 University Ave
Halifax NS B3H 1V8, Canada
Dr. Xu is a leading expert in pulmonary pathology in the Atlantic Canada. He graduated from Shanghai Medical University (Shanghai Medical College, Fudan Univresity) in China in 1982 and did thoracic surgical oncology residency there. He moved to Canada in 1987 as a postdoctoral research fellow, and completed pathology residency in the Dalhousie University in 1997. He obtained the fellowship certifications from both Royal College of Physicians and Surgeons of Canada and American Board of Pathology.
He is not only an expert in pulmonary pathology and cytopathology, he is also a cancer researcher and holds the position of Senior Scientist in the Beatrice Hunter Cancer Research Institute, Canada.
He has obtained research grants from various sources. Currently he is the Expert Panel Member in the Lung National Cancer Pathology and Staging Multidisciplinary Expert Panel, Canadian Partnership Against Cancer (CPAC). He is also the Chair, Pathology Working Group and Network Member, Pan-Canadian Lung Cancer Screening Network, CPAC, and the Chair, Pathology Working Group and Steering Committee Member, Lung Cancer Screening Network, Cancer Care Nova Scotia (CCNS), Canada.
In addition he holds memberships in the Correlative Sciences and Tumor Biology Committee and Lung Cancer Subcommittee in the National Cancer Institute of Canada (NCIC), and Medical Advisory Committee Member, Lung Cancer Canada (LCC). Dr. Xu’s research interest includes studying molecular profiling of human lung cancer in addition to pathological assessment of the tumor and selecting patients to receive personalized targeted therapy.
Dr. Xu and his colleagues established the QE II Lung Tumor Bank for research. Dr. Xu is the Director of the tumor bank which is one of the largest human lung tumor banks in the country and is certified by the Canadian Tumor Repository Network (CTRNet).
His research interests include: Lung cancer genotyping and Molecular profiling, Lung tumor banking, Metastasis and Early detection of lung cancer, Interstitial lung diseases.
ACADEMIC COMMITTEE MEMBER AND ADMINISTRATION
• (2014-now) Committee Member, Medical Advisory Committee, Lung Cancer Canada
• (2014-now) Committee Member, Lung Cancer Screening Steering Committee, Cancer Care Nova Scotia, Halifax, NS Canada
• (2014-now) Chair, Pathology Working Group, Lung Cancer Screening Program, Cancer Care Nova Scotia, Halifax, NS Canada
• (2013-Present) Chair, Pathology Working Group, The Pan-Canadian Lung Cancer Screening Network, Canadian Partnership Against Cancer, Canada
• (2013-Present) Committee Member, The Pan-Canadian Lung Cancer Screening Network, Canadian Partnership Against Cancer, Canada
• (2011-Present) Expert Panel Member, Lung National Cancer Pathology and Staging Multidisciplinary Expert Panel, Canadian Partnership Against Cancer, Canada
• (2007-Present) Committee Member, Correlative Sciences and Tumor Biology Committee, National Cancer Institute of Canada, Canada
• (2007-Present) Committee Member, CSTB-Lung Subcommittee, National Cancer Institute of Canada, Canada
• (2006-Present) Committee Member, Capital Health Research Ethics Board, Halifax, Canada
• (2006-Present) Committee Member, Mesothelioma and Thymoma Working Group, Lung Disease Site Committee, National Cancer Institute of Canada, Canada
• (2004-2005) Board of Directors, University Avenue Laboratory Medicine Association, Queen Elizabeth II Health Sciences Centre, Halifax, Canada
• (2002-2003) Chair, Anatomical Pathology and Cytology Standards Committee, Winnipeg Regional Health Authority, Winnipeg, Canada
• (2002-2003) Committee Member, Laboratory Medicine Standards Committee, Winnipeg Regional Health Authority, Winnipeg, Canada
• (2001-2003) Committee Member, Pathology Tissue Assessing Committee, Department of Pathology, University of Manitoba, Winnipeg, Canada
• (2002-2003) Committee Member, Clinical Oncology Standards Committee, Winnipeg Regional Health Authority, Winnipeg, Canada
• (1996-1997) Chief Resident, Pathology Residency Program, Dalhousie University, Halifax, Canada
• (1986-1987) Academic Secretary, Shanghai Lung Cancer Group, Shanghai Division of Chinese Medical Association, China
1. MacNeil A, Jiao S, Eachern L, et al. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer. Cancer Research. 2014; 74(1): 162-172.
2. Yeung P, Xu Z, Seeto D. Diltiazem Reduces Mortality and Breakdown ofATP in Red Blood CellInduced by Isoproterenol in a Freely Moving Rat. Model in Vivo Metabolites. 2014; 4: 775-789. doi: 10.3390/metabo4030775
3. Alcolado N, Conrad DJ, Poroca D, et al. Cystic Fibrosis Transmembrane Conductance Regulator dysfunction in VIP knockout mice. American Journal of Physiology Cell Physiology 2014. doi: 10.1152/ajpcell.00293.2013
4. Cressman S, Lam S, Tammemagi M, et al. Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. Journal of Thoracic Oncology. 2014.
5. Xu Z. Genomics and Molecular Profiling of Lung Cancer in Cancer Genomics:from bench to personalized medicine. Eds. Dellaire G,Berman J, Arceci R.Academic Press, Elsevier. 2013.
6. Xu Z. Pulmonary Pathology in Pathology Review ed. Zu-Hua Gao.BrushEducarion Inc.2013.
7. Vieira A ,Xu Z, Colp P, Marignani PA. Loss of lkb1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways.Plos One 2013; 8(2): e56567. doi: 10.1371/journal.pone.0056567
8. Marrie T, Costain N, Scola B, et al. The role of atypical pathogens in community-acquired pneumonia. Semin Respir Crit Care Med. 2012; 33(3): 244-256. doi: 10.1055/s-0032-1315636
9. Henzler D, Hochhausen H, Chankalal R, et al. Physiologic and biologic characteristics of three experimental models of acute lung injury in rats.Anesthesia and Analgesia. 2011; 112(5): 1139-1146. doi: 10.1213/ANE.0b013e3182104dac
10. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. The Journal of Thoracic Disease. 2010; 2: 48-51.
11. Xu Z, Bethune D, Manos D, et al. Pulmonary Hyalinizing Granuloma. Journal of Peking University (Health Sciences).2009; 41(4): 252-257.
12. Naugler C, Xu Z. Pancreatic adenoc arcinoma metastatic to the pineal gland. Journal of Clinical Neuroscience. 2008; 15: 1284-1286. doi: 10.1016/j.jocn.2007.08.022
13. Douglas SE, Bethune DC, Xu Z. Microarray analysis identifies pathways in progression of early stage lung adenocarcinoma: the importance of focal adhesion and ECM-receptor interactions. Pulm Res Respir Med Open J. 2014; 1(1): 21-31. doi: 10.17140/PRRMOJ-1-104